Biothera Pharmaceuticals to Present Clinical Data from Phase 2 Triple Negative Breast Cancer Study at ASCO 2019 Annual Meeting

    NEXT STORY
    Aptose to Present New Preclinical Data for CG-806 at the 24th Congress of The European Hematology Association
    PREV STORY
    Innovation Pharmaceuticals Announces Non-Binding Term Sheet Signed with Global Pharmaceutical Company to Develop and Commercialize Brilacidin for the Treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Actinium’s Chief Medical Officer, Dr. Mark Berger, to Present Talk Titled, Iomab-B: Radiolabeled CD45 at the 3rd Annual Expert Forum on Acute Leukemias and Myeloproliferative Neoplasms

    -  Dr. Berger’s presentation included in session on Immunotherapy and Bispecific Inhibitors in Acute ...

    author_avatar
    NASDAQ Market News

    Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone

    SOUTH SAN FRANCISCO, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), ...

    author_avatar
    NASDAQ Market News

    Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3

    author_avatar
    NASDAQ Market News